Oxford, UK – 13 November 2006: Oxford BioMedica (LSE: OXB), a leading gene therapy company, announced today that new preclinical efficacy results with its gene-based product for Parkinson’s disease, ProSavin, were presented at the 14th Annual Congress of the European Society of Gene Therapy (ESGT) in Athens, Greece, which was held on 9-12 November 2006 (http://www.esgt.org). The data showed, for the first time, that ProSavin outperformed the standard treatment for Parkinson’s disease, L-DOPA, in terms of efficacy without inducing any of the disabling dyskinesias (movement disorders) that occur following prolonged treatment with L-DOPA. Also, long-term data showed that ProSavin’s therapeutic benefit was maintained for at least 15 months, the most recent time point, without any loss of effect.
